Loading
A phase 2 trial of Glecirasib in non-small-cell lung cancer and small-cell lung cancer, run by Abbisko Therapeutics Co, Ltd, now recruiting.
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib is a phase 2 interventional study registered as NCT07164170 by Abbisko Therapeutics Co, Ltd, with 86 participants planned, started 2025-09-22 and due to reach its primary completion in 2028-12-30. Interventions recorded: ABSK043 in combination with Glecirasib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer.
Shares Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-molecule kinase inhibitors.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.